| 1.79 -0.01 (-0.56%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.2 | 1-year : | 2.57 |
| Resists | First : | 1.88 | Second : | 2.2 |
| Pivot price | 1.79  |
|||
| Supports | First : | 1.76 | Second : | 1.69 |
| MAs | MA(5) : | 1.79 |
MA(20) : | 1.79 |
| MA(100) : | 1.97 |
MA(250) : | 1.98 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 35.5 |
D(3) : | 42.1 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 2.51 | Low : | 1.44 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RFL ] has closed above bottom band by 42.8%. Bollinger Bands are 70.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.8 - 1.81 | 1.81 - 1.82 |
| Low: | 1.75 - 1.76 | 1.76 - 1.77 |
| Close: | 1.77 - 1.79 | 1.79 - 1.81 |
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Mon, 30 Oct 2023
Rafael Holdings Inc (RFL) Reports Q4 and Full Year Fiscal 2023 Financial Results - Yahoo Finance
Thu, 28 Oct 2021
Here's Why Rafael Holdings Is Plummeting Today - The Motley Fool
Fri, 24 Sep 2021
Rafael Holdings Continues to Expand its Management Team with a Highly Experienced Global Biopharmaceutical ... - PR Newswire
Tue, 14 Sep 2021
Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer - PR Newswire
Fri, 20 Aug 2021
Rafael Holdings Announces $104.2 Million Private Placement - PR Newswire
Mon, 21 Jun 2021
Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Real Estate
|
|
|
Industry:
Real Estate Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 1.591e+007 (%) |
| Held by Institutions | 20.5 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.496e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 839.7 % |
| Return on Equity (ttm) | -8.7 % |
| Qtrly Rev. Growth | 279000 % |
| Gross Profit (p.s.) | -0.84 |
| Sales Per Share | -5.38 |
| EBITDA (p.s.) | 245509 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.34 |
| Price to Cash Flow | 0.72 |
| Dividend | 0 |
| Forward Dividend | 43610 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|